Lifesaving treatment administered to only 10 percent of eligible stroke patients
from Cardiovascular Business
Two decades after being approved by the FDA for treatment of acute ischemic stroke, clot-dissolving medication intravenous alteplase is administered to just 10 percent of eligible patients, researchers from Georgia State recently reported in the American Journal of Emergency Medicine. Intravenous (IV) alteplase was tested and approved in 1996, and has since been shown to reduce disability and improve functionality in stroke patients, according to the research.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063